Education and Training
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: CREON
- biological: ZENPEP
- biological: ULTRESA
- biological: PANCREAZE
- biological: other non-sponsor pancreatic enzyme replacement therapy
- other: No pancreatic enzyme replacement therapy
- biological: PERTZYE
Eligibility
Inclusion Criteria:
The inclusion criteria for enrollment in the Base Study Population
- Diagnosed with cystic fibrosis,
- Enrolled in the Cystic Fibrosis Patient Registry
- Receiving medical care at a Cystic Fibrosis Foundation-accredited care center
providing data to the Cystic Fibrosis Patient Registry
Exclusion Criteria:
- None
Ages Eligible for Study
0 Months - 99 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Carlos Milla
650) 723-8325, (650) 736-9824
I'm interested